Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about LABT, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| 10% Bisphosphocin Topical Gel | Chronic Diabetic Foot Ulcers | Phase 2 · NCT05276401 | Terminated |
| 10% Nu-3 gel | Diabetic Foot Infection | Phase 2 · NCT06020235 | Not yet recruiting |
| 5% Bisphosphocin Topical Gel | Chronic Diabetic Foot Ulcers | Phase 2 · NCT05276401 | Terminated |
| 5% Nu-3 gel | Diabetic Foot Infection | Phase 2 · NCT06020235 | Not yet recruiting |
| Antibiotic | Diabetic Foot Ulcers (DFUs) | Phase 2 · NCT07565506 | Recruiting |
| Bisphosphocin Nu-3 | Diabetic Foot Infections | Phase 1/2 · NCT02737722 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
LABT holds $4.6M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.2M/quarter from operations, an estimated runway of 11.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed financial statements are issued.10-Q, Aug 2026
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LABT files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LABT and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →